Asset profile
rilzabrutinib
Small molecule
Evidence outlook · lead readout
NCT05104892 · Asthma
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05104892: The study was randomized and quadruple-blinded, compared rilzabrutinib with placebo, and enrolled 196 participants. Its primary endpoint was a clinical loss-of-asthma-control event, but no primary endpoint results are posted, so the treatment effect cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.